BST1: A Potential Drug Target and Biomarker for ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 2 Isoform X6

Target Name: BST1

NCBI ID: G683

BST1: A Potential Drug Target and Biomarker for ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 2 Isoform X6

Abstract:

BST1 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 isoform X6) is a key enzyme involved in the metabolism of cyclic ADP-ribose (CART), a key intermediate in the pathway of gluconeogenesis. The defect in BST1 has been associated with various diseases, including obesity, diabetes, and cardiovascular diseases. This article aims to provide an overview of BST1, its function in the metabolism of CART, and its potential as a drug target or biomarker.

Introduction:

Cyclic ADP-ribose (CART) is a key intermediate in the pathway of gluconeogenesis, which is a critical pathway for the production of energy in the body. It is synthesized from the amino acids Lys and Asp and the sugar glucose-6-phosphate (GSPC), which is converted to GSP+ by the enzyme BST1 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 isoform X6). BST1 catalyzes the conversion of GSPC to GSP+, which is then converted to GSP by the enzyme GSP cyclase. The final step in the pathway is the hydrolysis of GSP to release the energy-rich molecule NADH, which is then used to produce ATP.

BST1: A Key Enzyme for the Metabolism of CART

The defect in BST1 has been associated with various diseases, including obesity, diabetes, and cardiovascular diseases. BST1-deficient mice have an increased body weight and are resistant to the effects of obetalone, a drug that is used to treat obesity. Additionally, BST1-deficient mice have an increased risk of developing type 2 diabetes and cardiovascular diseases, as demonstrated by increased levels of blood glucose and insulin resistance.

BST1 is also involved in the regulation of cellular processes that are important for the development and maintenance of tissues, such as muscle and liver. BST1-deficient mice have decreased muscle mass and reduced liver weight, suggesting that BST1 plays a role in the regulation of muscle growth and liver development.

Potential Drug Target or Biomarker

The potential drug target for BST1 is the inhibition of its activity, which could be achieved by either pharmacological or genetic approaches. Pharmacological approaches include the use of small molecules, such as inhibitors of BST1, or the use of antibodies to target BST1. Genetic approaches include the use of CRISPR/Cas9 genome editing to introduce mutations in BST1 gene.

In addition to its potential as a drug target, BST1 may also be used as a biomarker for various diseases, including obesity, diabetes, and cardiovascular diseases. The levels of BST1 have been shown to be elevated in individuals with these diseases, and inhibiting BST1 activity may be a promising approach to treating these diseases.

Conclusion:

In conclusion, BST1 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 isoform X6) is a key enzyme involved in the metabolism of cyclic ADP-ribose. Its defect has been associated with various diseases, including obesity, diabetes, and cardiovascular diseases. The potential drug target for BST1 is the inhibition of its activity, while the potential biomarker for BST1 is the measurement of its levels in various tissues. Further research is needed to

Protein Name: Bone Marrow Stromal Cell Antigen 1

Functions: Catalyzes both the synthesis of cyclic ADP-beta-D-ribose (cADPR) from NAD(+), and its hydrolysis to ADP-D-ribose (ADPR) (PubMed:7805847). Cyclic ADPR is known to serve as an endogenous second messenger that elicits calcium release from intracellular stores, and thus regulates the mobilization of intracellular calcium (Probable). May be involved in pre-B-cell growth (Probable)

More Common Targets